Spots Global Cancer Trial Database for metastatic hepatocellular carcinoma

Every month we try and update this database with for metastatic hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)	NCT05003895	Hepatocellular ... Hepatocellular ... Metastatic Hepa...	Cyclophosphamid... CAR-T cell Fludarabine	18 Years -	National Institutes of Health Clinical Center (CC)
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs	NCT06228326	Lung Cancer, No... Lung Cancer Met... Solid Tumor, Ad... Advanced Cancer Lung Cancer, Sm... Metastatic Colo... Metastatic Rena... Metastatic Hepa... Metastatic Sarc... Metastatic Oste...	KB707	18 Years -	Krystal Biotech, Inc.
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver	NCT04175912	Metastatic Chol... Metastatic Hepa... Stage III Hepat... Stage III Intra... Stage IIIA Hepa... Stage IIIA Intr... Stage IIIB Hepa... Stage IIIB Intr... Stage IV Hepato... Stage IV Intrah... Stage IVA Hepat... Stage IVB Hepat... Unresectable Ch... Unresectable He... Unresectable In...	Carboplatin Paclitaxel Pevonedistat	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma	NCT04401800	Hepatocellular ... Unresectable He... Metastatic Hepa...	Lenvatinib Tislelizumab	18 Years - 70 Years	BeiGene
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma	NCT00142467	Hepatocellular ...	Gemcitabine Oxaliplatin Bevacizumab	18 Years -	Massachusetts General Hospital
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma	NCT01488487	Advanced Adult ...	Everolimus Pasireotide	18 Years -	UNC Lineberger Comprehensive Cancer Center
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	NCT05092373	Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ...	18 Years -	M.D. Anderson Cancer Center
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma	NCT03937830	Hepatocellular ... Hepatocellular ... Metastatic Hepa...	durvalumab Doxorubicin-Elu... TACE bevacizumab Tremelimumab	18 Years -	National Institutes of Health Clinical Center (CC)
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	NCT06066138	Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela...	Atezolizumab	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)	NCT05003895	Hepatocellular ... Hepatocellular ... Metastatic Hepa...	Cyclophosphamid... CAR-T cell Fludarabine	18 Years -	National Institutes of Health Clinical Center (CC)
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	NCT05075993	Metastatic Esop... Gastric Cancer Metastatic Head... Metastatic Hepa... Metastatic HPV ... Metastatic Ovar... Metastatic Soft... Metastatic Uvea...	LVGN3616 + LVGN... LVGN3616 + LVGN... LVGN3616 + LVGN... LVGN3616 + LVGN...	18 Years -	M.D. Anderson Cancer Center
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers	NCT04221893	Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Stage IV Adenoc... Stage IVA Esoph... Stage IVA Esoph... Stage IVA Gastr... Stage IVA Adeno... Stage IVB Esoph... Stage IVB Esoph... Stage IVB Gastr... Stage IVB Gastr... Metastatic Anal... Metastatic Colo... Metastatic Esop... Metastatic Gast... Metastatic Gast... Metastatic Hepa... Metastatic Mali... Metastatic Smal... Pancreatobiliar... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage IV Anal C... Stage IV Colore... Stage IV Hepato... Stage IVA Color... Stage IVA Hepat... Stage IVB Color... Stage IVB Hepat... Stage IVC Color...	Radiation Thera...	18 Years -	University of California, San Francisco
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma	NCT00142428	Hepatocellular ...	Cetuximab	18 Years -	Massachusetts General Hospital
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma	NCT00142467	Hepatocellular ...	Gemcitabine Oxaliplatin Bevacizumab	18 Years -	Massachusetts General Hospital
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer	NCT03695250	Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	IDO1 Inhibitor ... Nivolumab	18 Years -	University of California, Davis
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral	NCT04025567	Metastatic Hepa... Hepatocellular ...	vancomycin	18 Years -	National Institutes of Health Clinical Center (CC)
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma	NCT00142428	Hepatocellular ...	Cetuximab	18 Years -	Massachusetts General Hospital
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	NCT06066138	Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela...	Atezolizumab	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral	NCT04025567	Metastatic Hepa... Hepatocellular ...	vancomycin	18 Years -	National Institutes of Health Clinical Center (CC)
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab	NCT05199285	BCLC Stage B He... BCLC Stage C He... Locally Advance... Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Ipilimumab Nivolumab	18 Years -	Academic and Community Cancer Research United
RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	NCT05733598	Locally Advance... Recurrent Hepat... Metastatic Hepa...	RP3 atezolizumab bevacizumab	18 Years -	Replimune Inc.
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma	NCT00142467	Hepatocellular ...	Gemcitabine Oxaliplatin Bevacizumab	18 Years -	Massachusetts General Hospital
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	NCT06066138	Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela...	Atezolizumab	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer	NCT03695250	Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	IDO1 Inhibitor ... Nivolumab	18 Years -	University of California, Davis

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: